1. Home
  2. CORT vs IONS Comparison

CORT vs IONS Comparison

Compare CORT & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Corcept Therapeutics Incorporated

CORT

Corcept Therapeutics Incorporated

N/A

Current Price

$63.63

Market Cap

7.6B

Sector

Health Care

ML Signal

N/A

Logo Ionis Pharmaceuticals Inc.

IONS

Ionis Pharmaceuticals Inc.

N/A

Current Price

$26.61

Market Cap

6.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CORT
IONS
Founded
1998
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.6B
6.6B
IPO Year
2001
1996

Fundamental Metrics

Financial Performance
Metric
CORT
IONS
Price
$63.63
$26.61
Analyst Decision
Buy
Buy
Analyst Count
5
25
Target Price
★ $142.60
$67.83
AVG Volume (30 Days)
1.2M
★ 4.2M
Earning Date
11-03-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 21.71
EPS
★ 1.13
N/A
Revenue
★ $761,407,000.00
N/A
Revenue This Year
$52.09
N/A
Revenue Next Year
$44.73
$26.34
P/E Ratio
$57.37
★ N/A
Revenue Growth
★ 12.79
N/A
52 Week Low
$28.66
$26.55
52 Week High
$126.38
$86.74

Technical Indicators

Market Signals
Indicator
CORT
IONS
Relative Strength Index (RSI) 20.65 21.76
Support Level $30.24 N/A
Resistance Level $122.93 $46.07
Average True Range (ATR) 4.77 1.90
MACD -0.14 -0.56
Stochastic Oscillator 1.89 1.05

Price Performance

Historical Comparison
CORT
IONS

About CORT Corcept Therapeutics Incorporated

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.

About IONS Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).

Share on Social Networks: